Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY20 results · Jan–Mar 2020
Sun Pharma Advanced Research Company reported revenue from operations of ₹22.71 crore (down 73.2% from Q4 FY19) and net loss of ₹99.54 crore for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 22.71 | 84.83 | −73.2% | 19.60 | +15.9% |
| Other income | 3.12 | 4.43 | −29.6% | 0.71 | +339.4% |
| Total income | 25.83 | 89.26 | −71.1% | 20.31 | +27.2% |
| Profit before tax | (99.54) | (9.35) | Loss widened | (55.51) | Loss widened |
| Net profit for the period | (99.54) | (9.35) | Loss widened | (55.51) | Loss widened |
| EPS, basic (₹) | (3.80) | (0.37) | Loss widened | (2.12) | Loss widened |
| Net margin (%) | -438.3 | -11.0 | -283.2 |
Standalone
- Filed with BSE
- 03 Jun 2020, 20:08 IST
- Board meeting
- 02 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE